Compare AbbVie Inc (ABBV) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Salesforce Inc — how do they compare? AbbVie Inc trades at $248.5 (market cap $441.94B), while Salesforce Inc trades at $195.35 (market cap $161.73B). The key difference: AbbVie Inc is far larger — about 2.7× Salesforce Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | CRM | |
|---|---|---|
Market Cap | $441.94B | $161.73B |
Sector | Health | Technology |
52-Week High | $263.58 | $266.23 |
52-Week Low | $197.38 | $150.12 |
Enterprise Value | $506.19B | $191.77B |
Dividend Yield | 2.77% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Salesforce (CRM) trades at $197.51, up 2.47% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.88 beating expectations of $3.13. Technical indicators show bullish momentum with the price above key support levels, while valuation metrics remain reasonable with P/E of 22.89 and P/S of 4.29. Recent corporate actions include a $0.44 dividend declaration for July 2026 payment.
The outlook remains positive with analyst consensus price target of $230.61 representing 17% upside potential. Strong revenue growth trajectory ($37.9B in 2025 to $42.8B projected for 2026) and expanding profit margins (16.35% to 18.73%) support continued appreciation. Key risks include AI-driven sector volatility and macroeconomic headwinds affecting software spending, but the company's dominant market position and consistent execution provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
